tetano
Editor, Senior Moderator
Blood
. 2022 Jun 2;blood.2021014527.
doi: 10.1182/blood.2021014527. Online ahead of print.
Anticoagulation in Hospitalized Patients with COVID-19
Lisa Baumann Kreuziger[SUP] 1 [/SUP], Michelle Sholzberg[SUP] 2 [/SUP], Mary Cushman[SUP] 3 [/SUP]
Affiliations
Abstract
Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit of therapeutic heparin in hospitalized non-critically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research has improved care of hospitalized patients with COVID-19.
. 2022 Jun 2;blood.2021014527.
doi: 10.1182/blood.2021014527. Online ahead of print.
Anticoagulation in Hospitalized Patients with COVID-19
Lisa Baumann Kreuziger[SUP] 1 [/SUP], Michelle Sholzberg[SUP] 2 [/SUP], Mary Cushman[SUP] 3 [/SUP]
Affiliations
- PMID: 35653590
- DOI: 10.1182/blood.2021014527
Abstract
Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit of therapeutic heparin in hospitalized non-critically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research has improved care of hospitalized patients with COVID-19.